Merit Medical Receives 510(k) Clearance for ASAPLP™ Low Profile Aspiration Catheter

I’m pleased to announce that we have received 510(k) clearance for the ASAPLP Low Profile Aspiration Catheter, a new low-profile addition to our ASAP® line of aspiration catheters. The ASAPLP received the CE mark on August 30.

asaplp

The ASAPLP is designed to remove fresh, soft emboli and thrombi from vessels of the arterial system.

QUICK ASPIRATION

  • Fits into 6F guide catheter of ≥0.066” with ease
  • A 4F catheter designed for maximum aspiration
  • Long 30 cm hydrophilic coating promoting deliverability
  • Longer 20 cm rapid exchange lumen designed for better wire trackability

EFFECTIVE

  • 100% stainless steel braided, kink resistant 145 cm low profile aspiration catheter
  • Improved tip radiopacity due to radiopaque platinum iridium marker band
  • Bright colored wire exchange lumen

OPTIONS

  • Packaged with stiffening stylet

ASAPLP is Merit Medical’s latest innovation for quick, effective aspiration! For more information on the ASAP line of aspiration catheters, see the the Aspiration Catheter Family Brochure.

Elizabeth Pratt
Senior Product Manager

ask 4 UFE - Uterine Fibroid Embolization

Cynthia Bailey, The Real Housewives of Atlanta Cast Member, Will Undergo Uterine Fibroid Embolization on November 17 Episode

Cynthia Bailey revealed that she had fibroids in last week’s episode of the Real Housewives of Atlanta. Cynthia complained of heavy bleeding and long menstrual periods and the toll it was taking on her body and her personal life.

On the episode, set to air on Sunday, November 17 at 8 PM Eastern time, the cameras will be present when Cynthia undergoes a uterine fibroid embolization (UFE) procedure. Cynthia described the results of her UFE procedure in a recent interview as “life changing.” “Everything has changed and it has been amazing. I’m so glad I took care of it.” She said that she decided to share this experience to promote public awareness of uterine fibroids.

Uterine fibroids affect millions of women between the ages of 20 and 50 and are more common in African American women. Bailey hopes that fans will be inspired by her story.

Merit Medical sponsors an informational resource, the ask4UFE.com website, devoted to educating women about fibroids, treatment options, and UFE. The website includes a Physician Locator Tool to help women find physicians in their area who perform the UFE procedure.

ask4ufe logo

Merit Medical also offers embolization products that are used in uterine fibroid embolization (UFE) procedures: Embosphere® Microspheres and Bearing nsPVA™ nonspherical polyvinyl alcohol embolization particles. UFE is a less invasive treatment than hysterectomy. Go to http://www.ask4UFE.com today to determine if UFE is the right treatment option for you.

Comparison of Radiofrequency-targeted Vertebral Augmentation with Balloon Kyphoplasty for the Treatment of Vertebral Compression Fractures: 2-year Results.

Bornemann R, Jansen TR, Kabir K, Pennekamp PH, Stüwe B, Wirtz DC, Pflugmacher R. J Spinal Disord Tech. 2013 Pubmed PMID: 24247030 OBJECTIVES:

Evaluation of safety and effectiveness of radiofrequency-targeted vertebral, augmentation (RF-TVA) in comparison to balloon kyphoplasty (BK) for the treatment of, acute painful vertebral compression fractures (VCF) on the basis of matched pairs.

METHODS:

A total of 192 patients (116 females; 51 – 90 y) with VCF (n=303) at one to three, levels were treated with RF-TVA or BK. Functionality (ODI), pain (VAS), vertebral, height (anterior, middle) and kyphotic angle were evaluated over a two year period, (postoperatively, 3-4 d, 3, 6, 12 and 24 mo). Additionally, operating time and, occurrence of cement leakage were recorded.

RESULTS:

Pain and functionality were significantly improved after both treatments. In both groups, there was an increase in vertebral height and a decrease in kyphotic angle, which, remained relatively consistent during 24 months. The incidence of cement leakage was, 9.4% (n=9) in the RF-TVA group and 24.0% (n=25) in the BK group. The mean, operating time with radiofrequency kyphoplasty was 25.9±9.9 minutes and with balloon, kyphoplasty 48.0±18.4 minutes.

CONCLUSION:

RF-TVA is a safe and effective procedure for the treatment of vertebral compression, fractures when compared to BK. Improvement in pain and functional scores following, RF-TVA are durable through 24 months post-procedure and remained better than, those following BK at long term follow up. Operating time for RF-TVA is shorter and the, risk of cement leakage is lower. Both procedures provided similar results in vertebral, height restoration and reduction in kyphotic angle.

Merit Medical Exhibiting at 2013 AIM & VEITH Symposiums in New York, November 18-23, 2013

Merit Medical is proud to support AIM & VEITH, which will include educational sessions on the latest developments in interventional radiology, oncology, cardiology and vascular access.

We would like you to join us as we display our “Big Apple” welcome at AIM Booth 420 and VEITH Booth 110. Featured products will include:

We look forward to seeing you in New York City!

Patty Jabotte
Marketing Communications Manager

*Not currently available in the US  510(k) review pending

Merit Medical Adds 2 New Products for Assisting Hemostasis

safeguard

I’m excited about the recent announcement of Merit Medical’s acquisition of the Safeguard® products for assisting hemostasis. The Safeguard 12 cm and 24 cm Pressure Assisted Devices are latex-free, self-adhesive dressings designed to assist in obtaining and maintaining hemostasis. The 24-cm device is also indicated in the reduction of active compression time in femoral artery cannulation following diagnostic and interventional procedures with an ACT of 140 seconds or less, using a 6 F and smaller sheath size.

Safeguard Product Features

Ergonomic
•       Hands-free adjustable pressure of the puncture site
•       Inflatable bulb and standard Luer valve for easy inflation and deflation with any standard Luer syringe

Visibility
•       Clear window allows better visibility of the puncture site

Comfortable
•       Safeguard maintains a consistent pressure
•       87% of patients in a study indicated that Safeguard was “much more comfortable” than manual compression alone1

Secure
•       Adhesive provides a secure fit and minimizes movement or dislocation

Merit Medical’s growing portfolio of hemostasis products now includes the Safeguard, the Finale® and the RADstat® Radial Compression Devices and the Clo-Sur PLUS P.A.D.™ Antimicrobial Barrier.

Mark Heninger
Senior Product Manager

1 Roberts, A et al. Safeguard Manual Assist Technique: The SMAT Study. Cath Lab Digest, June 2008:38.

Merit Medical to Host Luncheon Symposium on Dialysis Techniques at CIDA 2013

Merit Medical is looking forward to attending the 2013 Controversies in Dialysis Access (CIDA) Meeting October 24-25 at the Westin St. Francis in San Francisco, California. Merit Medical will be hosting a luncheon symposium:
Dialysis Techniques and Clinical Outcomes
Moderator:
Stephen R. Ash, MD, Interventional Nephrologist, Ash Access Technology, Inc.
Speakers:
Saravanan Balamuthsamy, MD, Angiocare, Tucson, AZ
90 Day Patency Comparison: Self-Centering, Split-Tip Catheter vs Symmetric-Tip Catheter
Peter Hathaway, MD, Utah Vascular Clinic, Salt Lake City, UT
Peritoneal Dialysis – Percutaneous Case and Technique
Thursday, October 24,
12:00 PM-1:00 PM
California West Room
Merit Medical will also be sponsoring a Live Peritoneal Dialysis Catheter Placement Procedure by John Ross, MD, RMC Dialysis Access Institute, Orangeburg, South Carolina.
We hope you will join us for both the Luncheon Symposium.
Click on the links below to learn more about Merit Medical’s catheters and accessories for long-term hemodialysis and peritoneal dialysis including CentrosFLO® and ProGuide™ long-term hemodialysis catheters.
Chan Ream

Product Manager

Merit Medical Launches Embosphere® and HepaSphereTM Microspheres in Japan

I am pleased to announce that Nippon Kayaku (authorized distributor for Merit Medical Systems, Inc.) has received distribution and marketing authorization in Japan for Embosphere Microspheres and HepaSphere Microspheres.
The Japan Ministry of Health, Labour and Welfare held the “10th Investigative Commission about Expedited Introduction of Medical Devices, Which Are Strongly Needed in Medical Treatment” and it recommended the introduction of Embosphere and HepaSphere Microspheres to the Japan market. The recommendation was fulfilled by approval of both products in June 2013.
Embosphere Microspheres, the most clinically studied round embolic, provide consistent and predictable results for effective embolization in the treatment of uterine fibroids, hypervascular tumors, and arteriovenous malformations. Used worldwide in over 250,000 procedures since 2002, Embosphere Microspheres are the gold standard in uterine fibroid embolization, with Interventional Radiologists choosing Embosphere Microspheres in 73% of cases according to the FIBROID registry published in Obstetrics and Gynecology.
HepaSphere Microspheres are biocompatible, hydrophilic, nonresorbable, and conformable microspheres designed for controlled, targeted embolization. HepaSphere Microspheres also rapidly absorb aqueous solutions such as contrast media or saline. HepaSphere Microspheres enable physicians to optimize outcomes by more precisely matching the sphere size to the size of the targeted vasculature. In Japan, HepaSphere Microspheres are indicated for use in embolization of blood vessels for therapeutic or preoperative purposes in the following procedures:

  • Embolization of hepatocellular carcinoma
  • Embolization of metastases to the liver
Please visit our product pages for more information.
Noah Wong
Product Manager, Merit Medical

You Have Options For Treating Your Uterine Fibroids

Did you know that there are minimally-invasive treatment options available to treat uterine fibroids and the common symptoms associated with them: heavy bleeding, pelvic pain, and frequent urination?
In 2008, Uterine Fibroid Embolization (UFE) was recognized by the American College of Obstetricians and Gynecologists (ACOG) as an alternative to hysterectomy in the management of uterine fibroids.
      If you are not a good candidate for hysterectomy,
      If you want to avoid surgery for your fibroids,
      If you want to keep your uterus,
ASK ABOUT UFE!
UFE is a proven, effective option for treating uterine fibroids. To learn more about your options, go to www.ask4ufe.com.

Merit Medical Announces the Latest in Inflation Device Technology– the New basixTOUCH™

Merit Medical’s 35 ATM basixTOUCH Inflation Device is now available in the U.S., Europe, and many other countries around the world. The basixTOUCH is the latest innovation in inflation from Merit, and offers 35 ATM pressure capability as well as 30 mL of syringe volume to make it easier to accommodate a wide array of interventional balloons.

We surveyed hundreds of physicians and techs, and found a strong desire for a device that was easy on the hands, quick to set up, easy to inflate, and fast to deflate. From this feedback, Merit has designed a device with one-handed prep, an easy-to-turn quick-release handle.

basixtouch

The basixTOUCH expands your capacity with the innovation, quality, and reliability that Merit customers have enjoyed for over 25 years. To learn more about this new product and other products supporting interventional and diagnostic procedures, please contact your local Merit Sales Representative or visit us at www.merit.com.

Guido Sandulli
Director of Marketing, Interventional Cardiology

First Commercial Cases with STAR System in Europe

DFINE ANNOUNCES FIRST COMMERCIAL CASES WITH STAR TUMOR ABLATION SYSTEM IN EUROPE

San Jose, Calif. – October 9, 2013 – DFINE, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced the completion of the first European commercial cases with the STAR™ Tumor Ablation System for the palliative treatment of painful metastatic spinal tumors since the device received CE Mark approval last month.

The Targeted Radiofrequency Ablation (t-RFA) procedures using the STAR System were performed in Germany, Italy and the United Kingdom over the past two weeks.

According to Dr. Winston Rennie at the University of Leicester’s, Leicester Royal Infirmary who performed the first case in the UK, “t-RFA is one of the most innovative and exciting developments I have seen for the palliative treatment of painful spinal tumors in recent years,” he said. “The unique design of the STAR System allows me to deliver a very targeted and controlled ablation next to critical spinal structures, burn tumors and provide rapid pain relief in a single procedure. I was very pleased with the initial experience and can see a significant need for this in percutaneous cancer treatment and spine augmentation in the UK.”

The STAR System received 510k clearance in August 2010 and has demonstrated strong clinical outcomes in the U.S. and abroad. In September, the company announced the CE Mark approval and European product launch at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress.

“We are pleased with the very quick start in Europe and believe that it is indicative of the unmet clinical need for patients with painful spinal metastases,” said Greg Barrett, Chief Executive Officer of DFINE. “Our goal is to expand into centers across all European markets in an effort to make the therapy available to the many thousands of patients suffering from painful spinal tumors.”

About STAR™ Tumor Ablation System

t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit http://www.dfineinc.com/Product-Risk—SpineSTAR

About DFINE, Inc.

DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company. DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc.

Merit Medical™ Endovascular Snare System Interactive iPad App Version 2.0 Now Available!

I am pleased to announce the availability of the Merit Medical Snare Interactive App version 2.0 for the iPad.

The app is designed to help you select the appropriate size EN Snare® or ONE Snare® to use in a desired vein or artery. The app is also designed to provide the technical product specifications for reference and ordering purposes.

DOWNLOAD the Merit Snare Interactive App for the iPad by clicking on the following link:
http://cloud.merit.com/apps/meritsnares/index.html

ADD THIS INTERACTIVE APP TO YOUR iPAD

  • Open the link in Safari
  • Select the menu option “Add to Home Screen ”
  • Once complete, close Safari
  • Access the app directly by tapping on the Merit Snares app icon

Merit Medical’s EN Snare and ONE Snare Endovascular Snares
Accuracy.Reliability.Options.

Jesse Hansen
Director of Marketing – Interventional Radiology

CE Mark of Approval for STAR™ Tumor Ablation System

DFINE, INC. RECEIVES CE MARK APPROVAL FOR STAR™ TUMOR ABLATION SYSTEM

European Launch at CIRSE Annual Congress

SAN JOSE, Calif., Sept. 12, 2013 — DFINE, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced it has received CE Mark approval for the STAR™ Tumor Ablation System for treatment of painful metastatic spinal tumors. The company will launch the STAR System in Europe at theCardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress (Booth #12). CIRSE, the world’s largest and most prestigious conference in the field of minimally invasive image-guided therapies, will be held in Barcelona, Spain Sept. 14 – 19, 2013.

The STAR System received 510k clearance in the United States in August 2010 and has demonstrated strong clinical outcomes at centers across the country.

“We are very excited to bring this new treatment modality to Europe so that the hundreds of thousands of patients suffering from painful spinal tumors can receive the rapid pain relief that patients here in the U.S. have experienced. This represents a significant milestone for the company,” said Greg Barrett, Chief Executive Officer of DFINE.

About Metastatic Spinal Tumors

Cancer is a major public health problem throughout the world, with more than 3.4 million new diagnoses each year in Europe alone.1 When cancer is not found early, it can spread or metastasize to other parts of the body. A spinal tumor is a growth of cells (mass) in or around the vertebra near the spinal cord. It is estimated that 30 – 40 percent of cancer patients will likely develop metastatic spinal tumors.2

Patients suffering from painful spinal tumors have limited options. Many are in excruciating pain and unable to perform activities of daily living. Targeted RF ablation (t-RFA) with the STAR Tumor Ablation System was developed specifically for metastatic vertebral body tumors. The physician can target precisely where the device’s energy is delivered to heat and destroy the tumor, providing rapid and lasting pain relief in a single treatment.

1 Bray F, Ren HS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013 Mar1;132(5):1133-45. Epub 2012 Jul 26

2 Medscape Reference: Victor Tse, MD, PhD; Chief Editor: Stephen A Berman, MD, PhD, MBA, et al.

About STAR™ Tumor Ablation System

t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit http://www.dfineinc.com/Product-Risk—SpineSTAR

About DFINE, Inc.

DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company. DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc.

New! 7F Prelude® Sheath Introducers for Radial, Brachial, and Femoral Access from Merit Medical

Prelude 7F

I’m happy to announce the expansion of Merit Medical’s Prelude Radial Sheath Introducer product family. The 4F-6F product line now includes 7F sheaths for radial, brachial and femoral access. The new 7F sheaths are available in lengths of 7 cm, 11 cm and 23 cm; all kits include an 0.018” guide wire and 21G Merit Advance® angiographic needle.

The Prelude Sheath introducers provide excellent transitions for easy and smooth access to your patient. Custom kits including the sheaths can be designed to meet your specific needs.

Merit Medical is committed to providing excellent quality products for your access needs. To learn more about this new product and other products, please contact your local Merit Sales Representative or visit us at www.merit.com.

Stephanie Poulsen
Senior Product Manager, Merit Medical

Merit Medical Launches Bearing™ nsPVA (nonspherical polyvinyl alcohol)

We are pleased to introduce Bearing nsPVA Embolization Particles, the latest addition to Merit Medical’s broad array of interventional radiology embolization options.

bearingembopart

Merit Medical has been the market leader in spherical embolics (Embosphere® Microspheres) for over a decade and Bearing nsPVA will round out Merit’s embolization portfolio with an economical and nonspherical option. Merit’s established tradition for using state-of-the-art equipment and manufacturing processes has enabled us to develop this new product that offers enhancements over existing products in the current market.

Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters.

Bearing nsPVA is indicated for arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.

We look forward to Bearing nsPVA leading the way to targeted embolization.

Noah Wong
Product Manager

Cath Lab Digest Article Shows How a Merit Medical Custom Fluid Management Set Up Can Help Reduce the Risk of Air Embolism

recent Cath Lab Digest article, “Proposal of Manifold Variation for Use During Cardiac Catheterization,” reported that a new manifold set up used in 1,500 diagnostic catheterizations was “safe, very easy and convenient to use.”

In the article, a custom Merit Medical Fluid Management Kit was pictured showing a modified construction that allows physicians to inject medication while keeping the system closed during angiography, thus reducing the risk of air embolism associated with syringe exchanges.

HowardFigure1
Photo of Merit Medical fluid management products in the configuration suggested in the article.

By inserting a 3-way stopcock with pigtail attached to a 5 mL syringe on the heparin flush line, the operator can inject medication through the heparin flush line into the arterial circulation without exchanging the syringe from the manifold.

Click on the following link to watch our Fluid Management System & Custom Designed Kits video. To find out how to get this custom fluid management kit, contact a Merit Medical Representative today!

Mark Heninger
Senior Product Manager

Merit Medical Receives CE Mark for HepaSphere™ Microspheres 30-60 Micron Size

I am pleased to share that we have received the CE Mark for HepaSphere Microspheres’ newly developed 30-60 micron size. The new smaller size provides physicians with the ability to achieve more distal occlusions when embolizing hypervascular tumors and arteriovenous malformations. When packaged in their dry state, the new size microspheres measure 30-60 microns, but when reconstituted for use, they expand to 120-240 microns.

Hepashpere

HepaSphere Microspheres are biocompatible, hydrophilic, non-resorbable, and conformable microspheres designed for controlled, targeted embolization. HepaSphere Microspheres also rapidly absorb aqueous solutions such as contrast media, saline, or doxorubicin HCI. HepaSphere Microspheres 30-60 micron size, along with the currently available sizes, further enable physicians to optimize outcomes by more precisely matching the sphere size to the size of the targeted vasculature.
I am delighted to bring this new smaller size to the market together with a broad line of Interventional Radiology implant options designed to help physicians offer the best possible patient care.

Jim Kelly
Senior Director of Marketing, Merit Medical

HepaSphere Microspheres are not approved or available for sale in the United States.

Radiofrequency-targeted vertebral augmentation for the treatment of vertebral compression fractures as a result of multiple myeloma.

Erdem E, Akdol S, Amole A, Fryar K, Eberle RW. Spine 2013. Pubmed ID: 23591655

STUDY DESIGN: A retrospective review of a consecutive population of patients treated with radiofrequency-targeted vertebral augmentation (RF-TVA) for malignant vertebral compression fractures (VCFs). To investigate the safety and efficacy of RF-TVA in patients with malignant VCFs.

SUMMARY OF BACKGROUND DATA: The use of polymethylmethacrylate (PMMA) in vertebroplasty and balloon kyphoplasty for patients with recalcitrant pain after acute VCFs is shown to be safe, successful in stabilizing the VCF, and effective for the relief of pain after osteoporotic and malignant VCFs. RF-TVA using targeted cavity creation and ultrahigh viscosity PMMA delivery with a long handling time was developed to address the potential adverse issues that arise with vertebroplasty and balloon kyphoplasty.

METHODS: Between December 2008 and May 2009, a consecutive series of 66 RF-TVA procedures were performed for VCF secondary to multiple myeloma. Pre- and postoperatively, a standard 10-point visual analogue scale was used to assess back pain. Pain medication use and activity categories were defined and monitored for changes before and after RF-TVA. All patients were followed for 6 months postoperatively.

RESULTS: At 6 months postoperatively, significant improvement in pain, activity, and narcotic use was observed. Overall change in pain VAS score was statistically significant at 6 months (p< 0.001) and 75% of patients had a 6-month VAS of less than 4.There were no pulmonary or neurological complications, and one patient had radiographic evidence of asymptomatic leakage of PMMA into the vertebral disc space.

CONCLUSION: Optimum safety and efficacy results in the treatment of malignant VCFs with a novel RF-TVA technique in which controlled delivery of an ultrahigh viscosity PMMA is used for fracture stabilization. The deposition of PMMA with RF-TVA is predictable and uniform, and can be performed without PMMA handling constraints that may be encountered with vertebroplasty and balloon kyphoplasty.

Merit Laureate® Hydrophilic Guide Wire Available in New 0.025” Diameter

I’m pleased to announce that Merit will be offering a 0.025” diameter Merit Laureate Hydrophilic Guide Wire worldwide effective June 24, 2013. Smaller diameter guide wires are used in a number of different applications including standard arterial and venous angiography, PTA of chronic total occlusions, thrombolytic therapy, vena cava grams, and endovenous laser ablations.

The Merit Laureate is Merit Medical’s premier hydrophilic guide wire for the placement of devices during diagnostic and interventional procedures in radiology, cardiology, vascular surgery, nephrology, and urology.

The Merit Laureate offers

  • True 1:1 torque control for greater turn-for-turn responsiveness and rapid vessel selection
  • Reliable and lasting lubricity to minimize surface friction for navigating highly tortuous anatomy and rapid catheter exchanges
  • Enhanced lesion crossability
  • Dependable visualization under fluoroscopy

Available now in 0.025”, 0.035”, and 0.038” diameters, 80 cm to 260 cm lengths, standard and stiff body, with angled and straight tip configurations. Click here to watch our Merit Laureate Product Demonstration Video with side-by-side comparison to the market leader and a product feature animation.

Penny Goldman
Senior Product Manager

Merit Medical’s Valved One-Step™ Centesis Catheter Is Designed to Reduce Pneumothorax

Pneumothorax is a common complication resulting from a thoracentesis procedure. The pneumothorax may be caused by the needle puncturing the lung, or by air entering the pleural space from the needle or catheter. To reduce the risk of air entering the pleural space via the catheter, the Valved One-Step Centesis Catheter has a valve in the catheter hub.

The valve closes immediately upon removal of the needle. In the closed position, air is unable to enter the catheter as the patient breathes and thus reduces the chance of pneumothorax by air entering the pleural space via the catheter.

Visit the Merit Medical website to learn more about the Valved One-Step Centesis catheter.

Richard Collard
Senior Product Manager
Merit Medical Systems, Inc.

Depth Markers on Merit Medical’s ReSolve® Locking Drainage Catheter Help Ensure Safe and Accurate Placement

In a survey of Radiologists and Interventional Radiologists, roughly 80% said they measure the depth from the skin to the fluid collection prior to inserting a drainage catheter. Various reasons were given for this practice including “accuracy and safety”. To help ensure safe and accurate placement of the ReSolve Locking Drainage Catheter, depth markers are placed the entire length of the catheter beginning 1 cm proximal to the distal tip.

To help with accurate placement, some physicians mark the depth on their catheter. Having the marks pre-printed on the catheter will reduce the need for physicians to mark the catheter, potentially saving time with more accuracy.

Visit the Merit Medical website to learn more about the ReSolve Locking Drainage Catheter.

Richard Collard
Senior Product Manager
Merit Medical Systems, Inc.